Trabecular meshwork in neovascular glaucoma eyes after the intravitreal injection of bevacizumab

Neovascular glaucoma (NVG) is a severe consequence of ocular ischaemic disease. The mechanism of intraocular pressure (IOP) elevation is considered to be the increased permeability of the newly formed vessels,1 angle closure by the peripheral anterior synechia and intertrabecular neovascular tissue.2 3 The intravitreal injection of bevacizumab (IVB) was reported to be effective in the regression of new vessels.4 This injection may provide us with sufficient time to treat these patients with retinal photocoagulation. In addition, it may also be used as an adjunctive therapy for a mitomycin C (MMC) trabeculectomy to treat NVG. It remains to be elucidated as to how bevacizumab exerts its effects on the neovascular tissue in NVG. This study was carried out to examine the trabecular meshwork of eyes with NVG following the IVB. A dose of 1.25 mg (0.05 ml) of IVB (Avastin 100 mg/4 ml, Roche, Reinach, Switzerland) was given in the superotemporal quadrant 4 mm posterior to the limbus of the affected eyes of three patients. The underlying diseases …